Key Takeaways
- Price-led revenue, margin squeeze: FY22 revenue grew ~25% YoY, roughly two-thirds from price hikes, yet those hikes were insufficient to protect margins as raw material and energy costs surged, particularly in the last six months.
- Capex overshoots on input inflation: FY22 capex hit ₹240 Cr against a ~₹210 Cr target, pulled forward by faster execution and pushed up by rising steel, cement, and other input costs.
- Acetonitrile ramp is the near-term swing factor: The new 18,000-ton Dahej plant began production in Q4 and is ramping slowly; management hopes to push combined utilization to 60–70% and beyond, with the new plant’s cost of production lower than the existing capacity.
- Coal cost tripled, resetting the cost base: Power and fuel jumped from 8–9% of revenue to 13–14% as coal used for heating nearly tripled YoY, a headwind management has not fully passed on to customers over the last two quarters.
- What to watch next quarter: Whether raw material and coal costs actually retreat as management hopes, the pace of the acetonitrile ramp, and any concrete timeline on the ethylamines expansion and land acquisition for the next methylamines plant.
Margin Dynamics & Cost Pressure
- Raw material spike: Acetic acid, ammonia, and other key inputs rose by a large percentage, with acetic acid a substantial drag; management says many raw material prices are now coming down to reasonable levels and the worst is likely over, though volatility from China, Ukraine, and logistics makes it hard to call.
- Energy cost shock: Coal used for heating almost tripled from a year ago, driving a significant increase in other expenses in Q4; power, water, and fuel costs were the primary culprits.
- Pricing pass-through constrained: The company has not fully passed on cost increases over the last two quarters, taking a hit to margins itself, because aggressive price hikes risk customer distress and import competition.
- Self-help on energy: Adding 2 MW of solar capacity in the next three months, with another 2 MW planned for Dahej later in the year; also increasing turbine-based electricity generation within sites using coal to create high-pressure steam with an extraction scheme.
- Margin recovery bet: Management is optimistic margins will improve as cost increases are gradually passed on, a process that began toward the end of last year, and hopes to return EBITDA margin to the net 20s as soon as possible, contingent on raw material and coal costs easing.
Kothari: "This was a very challenging year for Alkyl Amines and our results are showing that. Most of our raw materials and energy input costs went up by a large percentage. We managed to pass some of the increases in our price to our customers, but that was not enough."
Acetonitrile: The Growth Bet & Competitive Landscape
- New capacity online: The 18,000-ton Dahej plant was commissioned toward the end of Q3 FY22 and began production in Q4; it is ramping slowly, and management hopes to push combined utilization across both plants to 60–70% and eventually higher.
- Cost advantage on the new plant: The expanded capacity will produce acetonitrile at a lower cost than the existing plant, aided by process optimization over time that has improved raw material and energy consumption.
- Green-route differentiation: Alkyl Amines manufactures acetonitrile from acetic acid and ammonia, a route with no side products and full recirculation within the system; management says many international players prefer this type of production.
- Demand tailwinds: Acetonitrile is a growing product with new uses emerging, including vaccine production; management is very positive on demand.
- Competitive capacity additions: INEOS is adding a 30,000-ton plant in Germany (by-product from acrylonitrile, two years out) and a domestic competitor is adding 15,000 tons; management is confident because a lot of material is currently imported and quality plus service will provide an edge.
- Price risk acknowledged: If supply outstrips demand, acetonitrile price could fall below ₹200 per kg; management calls this always a possibility.
Kothari: "We manufacture from acetic acid and ammonia which is a much, greener route. You can call it green because really speaking there are no side products. It is all getting recirculated within the system hardly anything goes out."
Capacity Expansion Pipeline
- Ethylamines: Existing plants are reaching capacity limits by the end of this year, triggering a large new plant at Kurkumbh; capacity will be quite high relative to existing capacities, and existing plants have the technology to switch to other amines. Commissioning is targeted for the last quarter of FY23 or first quarter of FY24, and the new capacity is expected to last at least five years.
- Methylamines: The Dahej expansion completed 1.5 years ago is likely to be used up; the Patalganga swing plant will probably be used for methyl next year or so. A new dedicated methylamines plant is planned two to three years down the line, with capacity not less than 150 tons per day (~45,000 tons).
- Land acquisition for methylamines: Management is already looking for land and expects to have suitable land in the next six months to a year.
- DMF optionality: The company currently lacks DMF capability but has the process; dimethylamine is needed for making DMF, and at some stage management may pursue it.
- Butylamines restart: Production was stopped earlier but remains a growth opportunity that may be restarted.
- New specialty chemicals: Several products are in the development and feed-marketing stage; names are undisclosed, and management will only talk about them once they become commercial.
Patel: "It is always a possibility there have been periods of time when there has been an overhang of capacity and there have been periods of time when both of us have been behind the curve and there has been a shortage but this is part of the business and it is a cycle sometimes you are ahead, sometimes you are behind..."
Volume Growth & Competitive Dynamics
- Volume growth gap vs competitor: Alkyl Amines’ volume grew 10–11% while a domestic competitor’s volume rose ~34%; management attributes part of the gap to Dimethylformamide (DMF), a product Alkyl Amines does not manufacture.
- Long-term volume trajectory: Management agrees with a historical 10–15% volume increase and does not see things changing looking forward, subject to customer issues with Chinese intermediates getting sorted out.
- Revenue mix stability: The pharma/agro split has not shifted meaningfully, moving perhaps 2 percentage points here and there with no directional trend.
- Export vs domestic: The ratio may tilt slightly more toward exports going forward but not significantly; domestic market growth remains the primary driver of capex decisions.
- Import competition constraint: Only one product, monoisopropylamine, has import duty protection, and only against three Chinese suppliers; this limits pricing power when domestic prices rise.
Patel: "I agree with you there we have always managed that 10% to 15% increase and I think looking forward I do not see things changing. Of course given all the nightmares that our customers are having with the Chinese intermediates they use, sometimes it is difficult to keep the volumes up but looking forward I think all that will get sorted out sooner or later."
Pricing Philosophy & Market Structure
- Market-driven pricing with structural limits: Prices are set by all producers and competitors, who share similar cost structures because their technologies are similar; sooner or later prices settle to a level acceptable to the market.
- Pass-through is a balancing act: Management is trying to pass cost increases on but cannot simply raise prices because customers would face distress and imports would undercut; the company has been absorbing part of the hit itself over the last two quarters.
- Cyclical capacity dynamics: Periods of capacity overhang and periods of shortage are part of the business; sometimes the company is ahead of the curve, sometimes behind.
Patel: "Almost everything is market driven. However, the issue is that the market is set up by all the producers and the competitors and all of us, as it happens, have the same or similar cost structures given that our technologies are similar. So sooner or later the prices settle to a level which is acceptable to the market."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Ethylamines expansion commissioning | Large plant at Kurkumbh | Last quarter FY23 or first quarter FY24 |
| Solar capacity addition | 2 MW added | Next three months |
| Additional solar capacity | Another 2 MW at Dahej | Later in the year |
| Land acquisition for methylamines plant | Suitable land identified | Next six months to a year |
| New methylamines plant | Not less than 150 tons/day (~45,000 tons) | Two to three years down the line |
| Capex funding | Through internal accruals mainly; no term debt planned | Next two years |
| Ethylamines capacity sufficiency | New expansion to last at least five years | From commissioning |
| EBITDA margin recovery | Back to net 20s, contingent on raw material costs not going up further and coal costs coming down significantly | As soon as possible |
| Profit and turnover doubling | Management’s plan and hope | Next three years |
Key Metrics
| Metric | Q4 FY22 |
|---|---|
| Revenue growth | ~25% YoY, with 2/3rds to 70% from price and the rest from volume |
| Power, water, fuel cost | ~14% of revenue, up from 8–9% previously |
| Acetonitrile price | ₹250–280 per kg |
| Acetic acid price | ₹65–70 per kg, ranged from ₹35 to over ₹90 in the last 1.5 years |
| FY2022 capex | ~₹240 cr, against a target of ~₹210 cr |
| FY2023 capex guidance | ~₹300 cr, subject to no further cost escalation |
| Ethylamines current capacity | 22,000–24,000 tons |
| Ethylamines capacity addition | ~35,000 tons (100–125 tons/day) |
| Acetonitrile new capacity commissioned | 18,000 tons at Dahej, production started in Q4 FY22 |
| Acetonitrile total capacity | 28,000–30,000 tons across both plants |
| Overall amines capacity | ~100,000 tons currently, rising to ~130,000 tons post ethylamines expansion and ~175,000 tons after methylamines expansion |
| Methylamines capacity | 46,000 tons, expanded from 30,000 tons in FY2021 |
| Export share | ~20% of sales |
| India acetonitrile demand | 25,000–30,000 tons |
| Solar capacity addition | 2 MW in next 3 months, another 2 MW later in the year for Dahej |